Yeah, I think that this talk actually is now particularly pertinent given the FDA’s recent draft guidance on novel clinical trial designs, where the FDA has openly endorsed exciting new paradigms of how to think, conduct, and design clinical trials to accelerate discoveries, allow the use of more flexible designs, allow the utilization of historical data, focusing on also potential pathways for rare cancer types, and thinking a little bit more holistically about how to extract information from data in the best way possible...
Yeah, I think that this talk actually is now particularly pertinent given the FDA’s recent draft guidance on novel clinical trial designs, where the FDA has openly endorsed exciting new paradigms of how to think, conduct, and design clinical trials to accelerate discoveries, allow the use of more flexible designs, allow the utilization of historical data, focusing on also potential pathways for rare cancer types, and thinking a little bit more holistically about how to extract information from data in the best way possible.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
